Is There a Wegovy 24mg Dose, and What Should You Know?

Why do some sources mention a Wegovy 24mg dose?

The short answer is: they are wrong, or they are not talking about the UK. Wegovy's licensed strengths are fixed by the MHRA on the basis of the clinical programme Novo Nordisk submitted. No 24mg pen or tablet exists. The most plausible routes to this number are a misreading of the 2.4mg weekly maintenance dose for the injection (the decimal point can get lost), confusion with investigational doses tested in early-phase trials but never brought to market, or material copied from non-UK sources where different products or naming conventions apply.

A quick check takes under a minute: the NHS medicines page for semaglutide lists every licensed strength. If a number you have read does not appear there, treat it with scepticism. The same page covers common side effects, storage and what to do if a dose is missed, it is the plain-English reference most people should bookmark alongside their Patient Information Leaflet.

Clinically, jumping to an unlicensed dose would also make no pharmacological sense. The titration schedule exists specifically to let your gut adjust to semaglutide gradually; skipping steps is associated with worse tolerability, not better results.

What are the real Wegovy injection strengths, and how does the schedule work?

The injection pathway, as described in the SmPC, begins at 0.25mg weekly for the first four weeks, a tolerability step rather than a therapeutic one. From there the prescriber titrates upward: 0.5mg, then 1mg, then 1.7mg, reaching the standard maintenance dose of 2.4mg. Each rung stays in place for roughly four weeks before the next increase is considered. For more on how that step-up feels in practice, the 0.25mg-to-1mg stretch of the schedule is a common point of curiosity for people just starting out.

In January 2026, the MHRA approved an additional maintenance option: 7.2mg weekly, initially supplied as three 2.4mg pens taken in the same week. A dedicated single-dose 7.2mg pen followed in April 2026. Trial data at this higher dose showed around 20.7% average weight loss over 72 weeks, approaching the results seen with tirzepatide at its highest strength. This pen carries a BMI threshold of 30 or above; it is not licensed for the cardiovascular indication.

The prescriber decides when, or whether, a patient is a candidate for the 7.2mg step, based on response and tolerability at 2.4mg. Patients do not self-select their maintenance dose.

Does the oral Wegovy tablet change how the numbers look?

Yes, in the sense that the tablet schedule runs to much higher milligram figures, which may be part of where the '24mg' confusion originates. The once-daily Wegovy tablet, approved by the MHRA on 11 June 2026 as the first licensed oral GLP-1 medicine for weight management in the UK, climbs through 1.5mg, 4mg and 9mg to a 25mg maintenance dose. It is worth reading the full Wegovy dose overview if you are comparing the injection and the tablet, because the milligram numbers are not equivalent, oral bioavailability is lower, so the tablet needs a higher dose to achieve a comparable effect.

The tablet is taken first thing in the morning, on a completely empty stomach, with a small amount of plain water. At least 30 minutes must pass before any food, drink or other medicines. No refrigeration is needed, which is a practical advantage for people who travel frequently. NICE has not yet issued a technology appraisal for the oral tablet, so it is currently available through private prescription only.

The question of whether the injection or the tablet suits you better is a clinical one. Factors your prescriber weighs include BMI, any history of gastrointestinal conditions, whether you have been on the injection previously, and practical preference. If you are considering the final injection step before a potential switch, you can read about what the 2mg Wegovy stage involves as part of that decision. You can also explore how Wegovy works in more detail before your consultation.

How should you approach getting the right Wegovy dose prescribed?

Semaglutide in either form is a prescription-only medicine. The prescriber who issues your prescription decides the starting point and all subsequent increases; you cannot increase your own dose or switch formulations without a fresh clinical review. That clinical oversight is not a bureaucratic hurdle, it is what keeps the titration safe and the supply chain legitimate.

If you are thinking about starting Wegovy and want to understand whether you are likely to be eligible, the licensed criteria are: a BMI of 30 or above, or 27 to 29.9 alongside at least one weight-related health condition such as high blood pressure, raised cholesterol or obstructive sleep apnoea. Lower BMI thresholds apply for some ethnic backgrounds under UK guidance. NHS access exists through specialist weight management services under NICE guidance, though waiting times can be long; the routes to obtaining Wegovy legally in the UK page covers both options plainly.

At nume, every consultation is personally reviewed by a GPhC-registered Independent Prescriber. There is no algorithm making the call. If you order before 12pm Monday to Friday and your prescription is approved, treatment is dispatched the same day and delivered free by DPD the next working day. For a full look at what is covered in one price, the treatment page sets it out without small print. If you are ready, you can start your free consultation there.